Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Globe Newswire•19/10/2026•16:05 ET
0
Key Highlights
- ➤Pliant will present Phase 1 study data for PLN-101095 at ESMO Congress 2026
- ➤FORTIFY Phase 1b trial is enrolling ICI-refractory solid tumor patients
- ➤Trial covers NSCLC, high tumor mutational burden tumors, and clear cell renal cell carcinoma
- ➤PLN-101095 is dosed at 1,000 mg twice daily before pembrolizumab addition
Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.
Get started
Create a free account to read the full story.